Third, YY1 was analyzed in six cases of advanced EGFR-mutant lung adenocarcinoma with disease relapse following first-line EGFR inhibitor treatment (Fig. 6D; Supplementary Table 3), which showed that YY1 levels rebounded to baseline in recurrent tumors (Fig. 6E). This evidence concerns the gene YY1 and lung adenocarcinoma.